Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.6, a high estimate of $64.00, and a low estimate of $39.00. A decline of 4.44% from the ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology ...

Ionis Pharmaceuticals (NASDAQ:IONS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.In the table below, you'll find a summary of ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $59.00. Yaron Werber’s rating is based ...

Review Ionis Pharmaceuticals Inc (IONS:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $68.00. Jason Gerberry has given his ...